The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

In the past decade, bacteria‐based cancer immunotherapy has attracted much attention in
the academic circle due to its unique mechanism and abundant applications in triggering the …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma
accounts for the majority of skin cancer–related deaths, but treatment is usually curative …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …

B cells are capable of a wide range of effector functions including antibody secretion,
antigen presentation, cytokine production, and generation of immunological memory. A …

The development of immune checkpoint inhibitors [monoclonal antibodies targeting
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD …